A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of MK0557 in Obese Patients.
Phase of Trial: Phase III
Latest Information Update: 18 Apr 2014
At a glance
- Drugs MK 0557 (Primary)
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 10 Jun 2017 Biomarkers information updated
- 22 Sep 2009 Trial phase changed from II/III to III as reported by ClinicalTrials.gov.
- 30 Jul 2008 Status changed from in progress to completed according to ClinicalTrials.gov.